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| BACKGROUND
Sickle-cell disorders (SCD) affect the structure of haemoglobin and result in episodes of acute pain, chronic anaemia and progressive organ damage. Recent improvements in life expectancy for people affected with SCD have been attributed to earlier detection and improvements in comprehensive management. 1 SCD is a relatively common condition, with approximately 12 000-15 000 affected individuals in the UK. 2, 3 Whilst the condition is most common in people of African origin, SCD may occur in any ethnic group. 3 SCD is caused by mutations in the β-globin gene. Inheritance is autosomal recessive, so both parents must be carriers of a mutation for the baby to be at risk of SCD. In the UK, there is a universal neonatal screening programme for SCD and carrier screening is offered through an antenatal haemoglobinopathy screening programme that aims to offer screening by 10 weeks in pregnancy. 4 Prenatal diagnosis of SCD is the most frequently requested prenatal test for a single gene disorder in the UK, 5 and currently requires invasive testing (chorionic villus sampling or amniocentesis) which carry a small risk of miscarriage 6, 7 and can only be carried out after 11 weeks in pregnancy. A safe alternative is on the horizon, with proof-of-concept studies showing that non-invasive prenatal diagnosis (NIPD) based on analysis of cell-free DNA (cfDNA) in maternal plasma may be possible for SCD. 8 NIPD can be performed early in pregnancy (9-10 weeks) and requires only a maternal blood sample, thereby removing the risk of procedure-related miscarriage associated with invasive diagnostic tests. It is anticipated that NIPD for SCD will be diagnostic and there will be no need to confirm NIPD with invasive testing. As such, NIPD could be considered as a replacement for invasive testing.
It is important that research exploring views of NIPD is carried out alongside the technical development of these new tests to ensure that social and ethical issues are addressed and stakeholder needs are met.
Previous research exploring views of NIPD for single gene disorders, including SCD, has been undertaken using qualitative interviews and focus groups with carriers of single gene disorders and health professionals. [9] [10] [11] To expand this work, we have utilized a quantitative approach that includes a discrete choice experiment (DCE). DCEs allow us to look closely at people's decision-making processes when making choices about prenatal testing. This is done by giving participants a series of hypothetical options for prenatal tests with differing attributes and asking them to choose between them. Analysing the choices, they make will identify the test attributes that are most important for decision making. We will also gain insights into people's willingness to trade one attribute for another. DCEs have been used to reveal preferences for screening and diagnostic tests for Down syndrome, [12] [13] [14] [15] [16] [17] and we have also used a DCE to look at preferences for the prenatal diagnosis of cystic fibrosis. 18 Here, we used a DCE to explore service user and health professional preferences for three key attributes of prenatal diagnostic tests for SCD: accuracy, time of test and risk of miscarriage. We also examined views on NIPD, including expected uptake. We tested two hypotheses:
1. Service users and health professionals will differ in their preferences for the three attributes of prenatal tests to be examined:
safety, accuracy and time of testing; 2. Service users will value the safety afforded by NIPD and hypothetical uptake of the test will be high.
| METHOD

| Ethical approval
Ethical approval was obtained from a National Research Ethics Service
Committee (10/H0714/3). Convenience sampling was used to participants to the study. For the service users, group potential participants were invited to anonymously complete the questionnaire whilst waiting for their clinical appointment. For the service provider group, potential participants were approached in person in their workplace and invited to anonymously complete a hard copy of the questionnaire.
| Recruitment
| Questionnaire design
The questionnaire had three components: (i) DCE choice sets, (ii) structured questions about prenatal testing and NIPD and (iii) demographic questions. Questionnaire design has been described previously, as the questionnaire used here was a modified version of the questionnaire used in our previous study looking at prenatal testing for cystic fibrosis. 18 Briefly, design of the choice sets followed DCE guidelines [19] [20] [21] and the attributes of safety, accuracy and time of test results were derived from focus groups with carriers of single gene disorders (SCD, cystic fibrosis and thalassaemia). 10 The attributes and levels used in the DCE choice sets are presented in Table 1 children. Demographic questions for health professionals covered job title, years in role, age and gender.
| Analysis
DCE analysis followed published guidance. [19] [20] [21] The DCE preference data were analysed using a conditional logit regression model as previously described. 18 As the sign (+ or −) of the coefficients from the regression analysis shows the direction of the preference, we expected positive coefficients for accuracy and no miscarriage risk and a negative coefficient for timing, which would indicate a preference for earlier test. Notably, as the different attributes do not have the same unit of change, the absolute value of the coefficients cannot be directly compared. Consequently, to compare the preferences of service users and service providers, a common scale was created by calculating the marginal rates of substitution (MRS) as a ratio of the coefficients of two attributes. 20 Descriptive statistics was used for the other components of the questionnaire. The software package Stata 12.0 (StataCorp USA) was used to perform all analyses.
| RESULTS
| Participants
Questionnaires were completed by 78 service users and 62 health professionals. Questionnaires were excluded if the internal consistency question was incorrect (patients n=7, health professionals n=0) or if the choice set was incomplete (patients n=4, and health professionals n=0). Ultimately, 67 service user and 62 health professional questionnaires were included in the analysis. The service user group included carriers of SCD (88.2%) and people affected with the condition (18.8%). The majority were female (89.4%).
A small proportion had a child with SCD (16.4%). Health professionals were predominately midwives (88.1%) and female (91.8%).
Demographic information for service users and providers is summarized in Tables 2 and 3 .
| Regression results
Service users and providers prefer a test with greater accuracy, early testing and no risk of miscarriage ( 
| Marginal rates of substitution
The MRS demonstrates the strong preference held by both service users and health professionals for a test with no risk of miscarriage.
Notably, service users were prepared to wait longer and accept lower accuracy compared to service providers for a test that had no risk of miscarriage (Table S1 ).
| Ranking of attributes
Participants ranked the importance of five attributes of prenatal tests:
safety, early testing, accuracy, financial cost and comprehensive information (Tables S2 and S3 ). Safety was ranked highest by service users (43.2%) followed by full information (21.6%). Accuracy was ranked highest by health professionals (45.6%) followed by safety (42.1%).
Cost was ranked lowest by both service users (86.5%) and health professionals (57.9%).
| Views on prenatal testing and the introduction of NIPD
When service users were asked whether they would have invasive testing for SCD, 63.1% said they have had or are likely to have invasive testing, with the most common reasons for testing being to "help make a decision about whether or not to continue the pregnancy"
(47.4%) and "to plan and prepare for the possible birth of a baby with SCD" (36.8%) ( In some cases, numbers may not add up to total N due to missing data. Percentages may not add up to 100 due to rounding.
whether they would have NIPD for SCD if it was available, 93.8% indicated that they would have NIPD. The majority of service users (73.4%) said that they would be prepared to pay for NIPD.
All participants were asked their views on pressure to have prenatal testing for SCD and whether they felt that offering NIPD would increase feelings of pressure to have a diagnostic test (Table 6 ).
Approximately half of both the service users (55.4%) and health professionals (52.5%) thought that pressure to have prenatal testing would increase if NIPD for SCD became available. Half of the service providers (50%) and more than half of service users (57.1%) felt that there was already pressure to have prenatal testing for SCD. The most frequently cited source of pressure was health professionals for both service users (46.5%) and providers (36.9%).
Forty-three (64.2%) service users responded to the question on what they saw as the benefits of NIPD. These primarily fell into three categories: no miscarriage risk (n=21); decision making, knowledge and preparation (n=17); and simpler and less stressful testing (n=6).
Fifty-nine (95.2%) health professionals described potential benefits of NIPD, with the majority mentioning decision making, knowledge and preparation (n=46); no miscarriage risk (n=15); and early diagnosis (n=11). Forty-five service users reported that they had no concerns (67.2%) and five said they had concerns but did not elaborate. Twentynine (46.8%) health professionals reported that they had no concerns.
Twenty-six (41.9%) health professionals described concerns, with the most common being increased pressure to test and terminate (n=11), availability of appropriate counselling (n=7), accuracy (n=6) and costs (n=4).
To address the question of whether health professionals thought NIPD should only be offered if it would change pregnancy management, a question was included asking whether NIPD should only be offered to women considering termination of pregnancy. Only four (6.6%) strongly agreed or agreed compared to 57 (93.4%) who strongly disagreed or disagreed.
| DISCUSSION
The aim of this study was to determine the preferences held by potential service users and providers for prenatal tests for SCD. Test safety was an important driver of decision making for both groups. 24 This is particularly pertinent in offering NIPD for SCD as previous research with women offered carrier testing for SCD during pregnancy indicated that the woman in the study accepted that health professionals had authoritative knowledge and the fact that screening was offered implied that having a baby with SCD would not be a good outcome. 25 Careful pretest counselling is needed to avoid parents feeling pressured to test and to allow them to make choices in keeping with their personal beliefs and values.
We found that willingness to have NIPD was high, with over 90% of service users saying they would have NIPD for SCD if it was available compared to 63% who said they would currently choose invasive testing. In addition, approximately 50% reported that risk of miscarriage was a barrier to invasive prenatal testing. These findings are similar to those of other studies exploring the potential uptake of NIPD for single gene disorders. 9, 10, 18, 26 Previous research has highlighted the difficulties in achieving timely partner testing within the UK Sickle Cell and Thalassaemia Screening Programme. 27 In 2013-2014, 15281 pregnant women were screen positive and 64% of partners had carrier screening. 28 It is possible that the number of women opting for NIPD for SCD may increase further because women whose partners decline carrier testing may find NIPD more acceptable than invasive testing when the exact risk of the child inheriting SCD is unknown. 10, 11 Overall, it appears that uptake of NIPD for single gene disorders will be high and many couples who would not consider invasive testing due to the risk of miscarriage would have NIPD.
The changes to the population accepting the offer of prenatal testing need to be considered in our approaches to counselling for NIPD for SCD. Most notably, many couples who would not previously have had prenatal testing may take up NIPD, and as a result may find themselves faced with a decision about termination of pregnancy.
This issue is particularly important in the setting of prenatal testing for SCD where in the UK and other countries a prenatal carrier screening programme is in place and there are existing concerns about informed consent processes 29 and carrier screening being presented as routine. 30 Without careful pretest counselling, the addition of NIPD to the care pathway has the potential to undermine informed consent as women newly identified as carriers of SCD may see NIPD as routine next step following a positive carrier screening result. 31 As such, it will be especially important to allow sufficient time in pretest counselling to talk through the impact of having NIPD which includes a discussion around the implications of the possible test results that is guided by the parents values and preferences. 32 It must be made clear to parents that accepting a "simple blood test" could lead to a decision about whether to continue or terminate the pregnancy. Individualized support through post-test counselling to assist decisions about next steps will be essential.
The cost of NIPD for SCD will need to be considered in strategies to implement this test in the NHS. The potential cost of NIPD relative to the current invasive testing pathway has been explored and NIPD for SCD using current approaches was estimated to cost £1210, which was £190 more than invasive testing. Moreover, the anticipated high uptake of NIPD we found in this study (approximately 95% compared to 65% for invasive testing) would result in an incremental cost of NIPD over invasive testing of £48,635 per 100 pregnancies at risk of SCD. As the increased uptake will include parents who would want to have NIPD for information only and would not consider termination of pregnancy, there is a need to address the issue of whether it is appropriate to direct resources to test when pregnancy management would not change. Consideration of this question must include the benefits of the information for early reassurance or for planning and preparation if the baby is found to be affected by SCD. 31 In the study, we report here only a very small proportion of health professionals (6.6%), when asked, thought NIPD should only be offered if it would change pregnancy management.
| Limitations
Several limitations of our study may mean that our findings are not widely generalizable. Recruitment was only conducted at two centres for service users and only one centre for service providers and both centres were located in central London. As this was not a random sample and convenience sampling was used, it is possible that sampling bias will limit the generalizability of our results. In addition, participants were self-selected and there may be responder bias towards people with strong pre-existing views on NIPD. Another limitation of the study was that the numbers of participants recruited were not sufficient to allow subgroup comparisons. In an equivalent study looking at NIPD for cystic fibrosis, we found there were differences in preferences between people affected with the condition and those who were carriers. 18 In addition, only a small number of men were recruited and their viewpoints may differ to those of women. The health professional group primarily comprised midwives and health professionals from other training backgrounds may have different preferences. In future studies, it would be useful to seek the views of other professionals and include people with both obstetrics and genetics backgrounds. As this is a stated preference study, it is possible that the choices made by participants may not reflect real-life decisions.
The DCE only included three attributes of prenatal tests, and in reality, many attributes are considered when making decisions about testing.
In addition, the DCE design does not address why these choices have been made or give insight into how the tests were perceived. Another important limitation is that participants' reported willingness to have NIPD is hypothetical and may not reflect uptake when the test enters clinical practice which has been seen in other studies looking at uptake of genetic testing.
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| CONCLUSIONS
When making decisions about prenatal testing for SCD, potential service users and providers do not place the same emphasis on the test attributes. It is likely that the safety of NIPD will be welcomed by parents and uptake will be high. It is therefore important that pretest counselling is balanced and not predominately focused on the safety of NIPD. Care must also be taken to minimize feelings of pressure to have NIPD. Considerations for implementation need to include current carrier screening and prenatal diagnosis pathways. Offering NIPD as a next step in the current pathway could create pressure to test at a time when news of carrier status is still being processed and decisions need to be made quickly about next steps. Thorough pre-and post-test counselling will be essential and NIPD should be offered by health professionals specifically trained in counselling for prenatal testing for SCD.
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